In a report released today, Irina Rivkind Koffler from Mizuho Securities maintained a Hold rating on Jazz Pharmaceuticals (NASDAQ: JAZZ), with a price target of $180. The company’s shares opened today at $158.46.
Rivkind Koffler commented:
“We believe this event was widely expected as “a matter of time”, but should provide some support to the stock, which has recently slumped with the tape.”
According to TipRanks.com, Koffler is a 5-star analyst with an average return of 9.4% and a 44.0% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Eagle Pharmaceuticals Inc, and Supernus Pharmaceuticals.
Currently, the analyst consensus on Jazz Pharmaceuticals is a Strong Buy with an average price target of $199.44.
See today’s analyst top recommended stocks >>
Jazz Pharmaceuticals’ market cap is currently $9.39B and has a P/E ratio of 21.98. The company has a Price to Book ratio of 3.27.
Based on the recent corporate insider activity of 88 insiders, corporate insider sentiment is negative on the stock. Most recently, in August 2018, Rick Winningham, a Director at JAZZ sold 16,639 shares for a total of $2,931,292.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry.